Tech news - autumn 2023

1 November 2023
Autumn 2023

A glance at what’s happening in the world of technology.

© Science Photo Library

1. Corticosteroid treatment for uveitic macular oedema shows promise

A clinical trial to evaluate the effectiveness of three different intravitreal treatments for persistent or recurrent uveitic macular oedema found that dexamethasone was significantly better at treating the condition.

Researchers looked at 225 eyes in 194 patients with minimally active or inactive uveitis and persistent or recurrent uveitic macular oedema in one or both eyes. Patients at 33 clinical centres across the US, UK, Australia and India each received one of three therapies: dexamethasone implant, methotrexate or ranibizumab.

At 12 weeks, dexamethasone was found to be significantly better at treating persistent or recurrent macular oedema, giving a 35% reduction in central subfield thickness compared with 22% for ranibizumab and 11% for methotrexate.

Sign in to continue

Forgotten password?

Not already a member of the College?

Start enjoying the benefits of College membership today. Take a look at what the College can offer you and view our membership categories and rates.

Related further reading

The College has provided key information to help you identify cases and guidance on managing circumstances that are relevant to optometry practices.

The College’s Research Excellence Awards recognise achievements in optometric research, and the way in which they enrich the whole profession.

The College of Optometrists offers support to hay fever sufferers on managing their symptoms.